Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-P17-087/177Lu-P17-088 in mCRPC
NCT05603559Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2023
- Primary completion
- Sep 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-P17-087 and 177Lu-P17-088 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Dosimetry of normal organs and tumors at 168 hours, Hematologic adverse events collection at 2 weeks and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
177Lu-P17-087177Lu-P17-088
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05603559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603559.